期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拉米夫定初始联合阿德福韦酯在慢性乙型肝炎治疗中的进展 被引量：7

下载PDF
导出
摘要 抗病毒治疗是改善慢性乙型肝炎（简称乙肝）患者预后的关键[1-2],既可改善患者临床症状及肝功能,还能减缓肝硬化进程,甚至实现肝组织结构重塑和肝硬化逆转[1-3]。干扰素是最早用于慢性乙肝治疗的抗病毒药物,但不良反应较多,且患者耐受性较差[4]。因此,目前慢性乙肝的抗病毒治疗倾向于使用其他抗病毒治疗方法,如口服核苷（酸）类似物[5]。
作者 邓孝林 郭进军
机构地区 重庆医科大学附属第二医院消化内科
出处 《检验医学与临床》 CAS 2013年第11期1460-1462,共3页 Laboratory Medicine and Clinic
基金 国家自然科学基金资助项目(项目编号:30972583)
关键词 拉米夫定 阿德福韦酯 抗病毒治疗 耐药性
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献4

二级参考文献34

  • 1崔金环,杨霞.慢性乙肝合并妊娠对孕妇及婴儿的影响及应对措施[J].中国误诊学杂志,2009,9(1):98-99. 被引量：4
  • 2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
  • 3蔡晧东,王玲,刘敏.乙型肝炎病毒感染妊娠妇女拉米夫定的应用及安全性[J].中华肝脏病杂志,2006,14(2):151-153. 被引量：20
  • 4Keeffe EB,Dieterich DT,Pawlotsky JM,et al.Chronic hepatitis B:preventing,detecting,and managing viral resistance.Clin Gastroenterol Hepatol,2008,6:268-274.
  • 5Yuen MF,Fung J,Wong DK,et al.Prevention and management of drug resistance for antihepatitis B treatment.Lancet Infect Dis,2009,9:256-264.
  • 6Lok AS,McMahon BJ.Chronic hepatitis B.Hepatology,2007,45:507-539.
  • 7Liaw YF,Leung N,Kao JH,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update.Hepatol Int,2008,2:263-283.
  • 8Locarnini S.Primary resistance,multidrug resistance,and crossresistance pathways in HBV as a consequence of treatment failure.Hepatol Int,2008,2:147-151.
  • 9European Association For The Study Of The Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B.J Hepatol,2009,50:227-242.
  • 10Liu F,Yu DM,Chen L,et al.Dynamic changes of hepatitis B virus quasispecies during early entecavir treatment in patients with different responses.APASL,2010:421.

共引文献73

同被引文献69

  • 1European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B [J]. J Hepatol, 2009,50 (2) : 227-242.
  • 2Sung JJ, Lai JY,Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg- positive chronic hepatitis B[J]. Hepatol, 2008,48 (5) :728-735.
  • 3Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology, 2007,45 (2) : 507-539.
  • 4European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J]. J Hepatol, 2012,57( 1 ) : 167-185.
  • 5Tenney D J, Rose RE, Baldick C J, et al. Long-term monitoring shows he- patitis B virus resistance to entercavir in nucleoside-naYve patients is rare through 5 years of therapy[J]. Hepatology, 2009,49 (5) : 1503-1514.
  • 6Ho EY,Yau T,Rousseau F,et al.Preemptive adefovir versus lamivudi- ne for prevention of hepatitis B reactivation in chronic hepatitis B pa- tients undergoing chemotherapy[J].Hepatology international,2015,9(2):224-230.
  • 7Rokx C,Rijnders BJ.Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine[J].Society of America,2015,60(11):1732-1733.
  • 8Woo HY,Choi JY,Yoon SK,et al.Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepa- titis B virus[J].Clinical and molecular hepatology,2014,20(2):168-176.
  • 9Hwang JA,Kim KB,Yang MJ,et al.Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients[J].Clinical and molecular hepatology,2015,21(2):131-140.
  • 10Hwang JA,Kim KB,Yang MJ,et al.Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients[J].Clinical and molecular hepatology,2015,21(2);131-140.

二级引证文献45

检验医学与临床
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部